Poging GOUD - Vrij
Beyond the Ticker: Why Unlisted Stocks Are Quietly Stealing the Spotlight
Mint Mumbai
|August 14, 2025
FY25 witnessed strong price and trading activity in unlisted local firms, with NSE gaining 115%
When we think of investments, the image is often of the stock exchange—a screen flashing green and red, prices shifting by the second, and the thrill of volatility. But the financial world has changed. Today, some of the most compelling opportunities lie outside listed markets.
The unlisted space—quieter, less reactive—has delivered extraordinary growth in recent years. FY25, in particular, was a landmark for investors and shareholders in unlisted companies. Giants like Tata Capital, Studds Accessories, Nayara Energy, Motilal Oswal Home Finance, Cochin International Airport, NSE, and MSEI saw surges in both price and trading activity.
The National Stock Exchange (NSE) delivered a staggering 115% return in just one year, creating not just wealth but also visibility for unlisted equities as a serious asset class. Yet, this segment comes with its own rules and risks, often unknown to the average investor.
Risks & rewards
Despite its appeal, the unlisted space can be unforgiving.
Valuation gaps: Without market-driven pricing, valuations rely on deep financial analysis—and often, speculation.
Liquidity constraints: Concentrated ownership among founders and early investors means fewer buyers and sellers. Exits can be difficult.
Dit verhaal komt uit de August 14, 2025-editie van Mint Mumbai.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint Mumbai
Mint Mumbai
Gen Alpha will make new rules for their workplace
Gen Alpha will expect hybrid workplaces, Al tools and 4-day weeks— offices unrecognizable to their parents’
3 mins
December 01, 2025
Mint Mumbai
EC extends electoral roll revision by a week to II Dec; final list on 14 Feb
The Election Commission on Sunday extended by one week the entire schedule of the ongoing special intensive revision (SIR) of electoral rolls in nine states and three Union territories amid allegations by opposition parties that the “tight timelines” were creating problems for people and ground-level poll officials.
2 mins
December 01, 2025
Mint Mumbai
THE PROBLEM IS NOT JUST ABOUT DYNASTIC POLITICS
These days Tejashvi Yadav is the target of intense trolling. Before him the Huda family in Haryana and Thackerays in Maharashtra got the same treatment. So, is the battle of victory and defeat in electoral politics a tussle between dynasts vs the rest? Absolutely not.
3 mins
December 01, 2025
Mint Mumbai
Green hydrogen: Fast fashion could help bump up demand
A boom in its use for clean synthetic inputs might make a difference
3 mins
December 01, 2025
Mint Mumbai
Let's be a bit more selective in using the word 'reforms'
Everybody should take a beat and think before uttering the word ‘reforms’ the next time. Glib usage, frequently in the wrong context, threatens to rob the word of its import.
3 mins
December 01, 2025
Mint Mumbai
As mid-cap alpha shrinks, should you consider passive strategies?
Advisers urge a balanced mix—add passives slowly and back strong, active managers, as mid-caps are still pricey
4 mins
December 01, 2025
Mint Mumbai
With $2.2 bn fund, ChrysCap has appetite for riskier bets
MD Saurabh Chatterjee details shift in global LP base, renewed focus on manufacturing
3 mins
December 01, 2025
Mint Mumbai
GDP growth of 8% plus: How to sustain this pace
Last quarter's economic expansion has cheered India but the challenge is to sustain a brisk rate for years to come. For private investment to chip in, revive infrastructure partnerships
2 mins
December 01, 2025
Mint Mumbai
INSIDE INDIA'S ATTEMPT TO TAME DEEPFAKES
Detection tools today are not universal or consistent across languages
5 mins
December 01, 2025
Mint Mumbai
APIs to innovation: Bulk drug makers ramp up CDMO bets
Once focused on low-margin active pharmaceutical ingredients (APIs), India’s bulk drug manufacturers are raising their ambitions, with several now investing heavily in research and development to win contract development and manufacturing work from global drugmakers.
2 mins
December 01, 2025
Listen
Translate
Change font size

